Kuwait Antifungal Drugs Market Size & Outlook, 2023-2030
Kuwait antifungal drugs market, 2018-2030 (US$M)
Related Markets
Kuwait antifungal drugs market highlights
- The Kuwait antifungal drugs market generated a revenue of USD 38.7 million in 2023 and is expected to reach USD 53.5 million by 2030.
- The Kuwait market is expected to grow at a CAGR of 4.7% from 2024 to 2030.
- In terms of segment, azoles was the largest revenue generating drug class in 2023.
- Echinocandins is the most lucrative drug class segment registering the fastest growth during the forecast period.
Antifungal drugs market data book summary
| Market revenue in 2023 | USD 38.7 million |
| Market revenue in 2030 | USD 53.5 million |
| Growth rate | 4.7% (CAGR from 2023 to 2030) |
| Largest segment | Azoles |
| Fastest growing segment | Echinocandins |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Azoles, Echinocandins, Polyenes, Allylamines |
| Key market players worldwide | Novartis AG ADR, Pfizer Inc, Bayer AG, Sanofi SA, Merck KGaA, Merck & Co Inc, GlaxoSmithKline, Abbott Laboratories, Enzon Pharmaceuticals Inc, Astellas Pharma Inc, Glenmark Pharmaceuticals |
Other key industry trends
- In terms of revenue, Kuwait accounted for 0.2% of the global antifungal drugs market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, Saudi Arabia antifungal drugs market is projected to lead the regional market in terms of revenue in 2030.
- Saudi Arabia is the fastest growing regional market in Middle East & Africa and is projected to reach USD 327.2 million by 2030.
Azoles was the largest segment with a revenue share of 47.8% in 2023. Horizon Databook has segmented the Kuwait antifungal drugs market based on azoles, echinocandins, polyenes, allylamines covering the revenue growth of each sub-segment from 2018 to 2030.
Kuwait has an invasive aspergillosis prevalence rate of 16.7%. The prevalence of candidemia has an incidence rate of 6.8 per 100,000 . Oral candidiasis has a prevalence rate of 1.7 per 100,000. Recurrent Candida vaginitis (>4×/year) has a high incidence of 2,595 per 100,000.
Allergic bronchopulmonary aspergillosis (ABPA) has a prevalence rate of 187 per 100,000 in the population suffering from respiratory diseases. Some of the key market players operating in the market are SPIMACO and Jamjoom Pharma.
Kuwait Ministry of Health (MOH) is the regulatory authority operating in Kuwait. The registration of medicines was governed by Ministerial Decree No. 361 of 2019 ("Decree"), which was published by Kuwait's Ministry of Health ("MOH") in January 2020. The Decree updates the various MOH regulations regarding the registration of pharmaceutical items and enhances the legislation governing pharmacies.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antifungal Drugs Market Scope
Antifungal Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Kuwait antifungal drugs market size, by drug class, 2018-2030 (US$M)
Kuwait Antifungal Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
